{"id":403,"date":"2025-11-15T14:10:16","date_gmt":"2025-11-15T14:10:16","guid":{"rendered":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/?p=403"},"modified":"2025-11-15T14:10:16","modified_gmt":"2025-11-15T14:10:16","slug":"des-avancees-prometteuses-dans-le-traitement-de-la-sla","status":"publish","type":"post","link":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/des-avancees-prometteuses-dans-le-traitement-de-la-sla\/","title":{"rendered":"Des avanc\u00e9es prometteuses dans le traitement de la SLA"},"content":{"rendered":"<p>L&#8217;ann\u00e9e derni\u00e8re a marqu\u00e9 un tournant dans la recherche de traitements pour la scl\u00e9rose lat\u00e9rale amyotrophique (SLA). Le nombre d&#8217;essais cliniques a plus que doubl\u00e9, passant de 28 en 2023 \u00e0 60 en 2024. Cependant, les traitements en phase avanc\u00e9e restent rares, avec seulement quelques candidats en phase 3. Pour une maladie qui a connu plusieurs \u00e9checs et manque d&#8217;options th\u00e9rapeutiques modificatrices de la maladie, chaque candidat restant repr\u00e9sente une opportunit\u00e9 majeure de perc\u00e9e. MediciNova, une entreprise californienne, est en pleine phase cruciale d&#8217;un essai clinique. Elle a r\u00e9cemment termin\u00e9 le recrutement de patients pour un essai de phase 2b\/3 d&#8217;une dur\u00e9e d&#8217;un an, testant son candidat m\u00e9dicament MN-166. Cet essai pourrait confirmer les r\u00e9sultats prometteurs des \u00e9tudes pr\u00e9c\u00e9dentes, sugg\u00e9rant que MN-166 pourrait modifier le cours de la maladie. Contrairement aux traitements ciblant une seule mutation g\u00e9n\u00e9tique ou voie biologique, MN-166 se distingue par son approche double action. Il inhibe les voies pro-inflammatoires et renforce les agents anti-inflammatoires, offrant ainsi une protection neuronale. Les r\u00e9sultats pr\u00e9liminaires montrent une am\u00e9lioration des scores fonctionnels chez certains patients. MediciNova utilisera des analyses suppl\u00e9mentaires pour \u00e9valuer l&#8217;effet global du m\u00e9dicament sur la maladie. En plus des am\u00e9liorations des scores fonctionnels et des taux de survie, ils examineront \u00e9galement l&#8217;analyse des r\u00e9pondeurs, qui \u00e9value le nombre de patients dont la maladie ne s&#8217;est pas aggrav\u00e9e. Le parcours clinique de MN-166 a \u00e9t\u00e9 long. Son principe actif, l&#8217;ibudilast, a d&#8217;abord \u00e9t\u00e9 approuv\u00e9 pour traiter l&#8217;asthme au Japon dans les ann\u00e9es 1980. MediciNova a repris le d\u00e9veloppement de ce m\u00e9dicament pour la scl\u00e9rose en plaques et d&#8217;autres maladies neurod\u00e9g\u00e9n\u00e9ratives. Le m\u00e9dicament est \u00e9galement test\u00e9 pour traiter plusieurs formes de d\u00e9pendance. Pour financer ses recherches, MediciNova a \u00e9vit\u00e9 les lev\u00e9es de fonds traditionnelles, pr\u00e9f\u00e9rant les subventions et les partenariats. La soci\u00e9t\u00e9 dispose actuellement de suffisamment de fonds pour poursuivre ses essais cliniques et pr\u00e9parer un dossier de demande d&#8217;approbation \u00e0 la FDA. Les r\u00e9sultats interm\u00e9diaires pourraient \u00eatre disponibles avant la fin de l&#8217;essai pr\u00e9vu en ao\u00fbt.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>L&#8217;ann\u00e9e derni\u00e8re a marqu\u00e9 un tournant dans la recherche de traitements pour la scl\u00e9rose lat\u00e9rale amyotrophique (SLA). Le nombre d&#8217;essais [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":404,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[414],"tags":[],"class_list":["post-403","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-nouvelles"],"_links":{"self":[{"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/posts\/403","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/comments?post=403"}],"version-history":[{"count":1,"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/posts\/403\/revisions"}],"predecessor-version":[{"id":417,"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/posts\/403\/revisions\/417"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/media\/404"}],"wp:attachment":[{"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/media?parent=403"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/categories?post=403"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/tags?post=403"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}